Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.
Myelofibrosis
chronic myeloid leukemia
clinical
systemic mastocytosis
thrombosis
translational
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
21
02
2022
received:
28
12
2021
accepted:
03
03
2022
pubmed:
4
4
2022
medline:
12
10
2022
entrez:
3
4
2022
Statut:
ppublish
Résumé
Despite much of the past 2 years being engulfed by the devastating consequences of the SAR-CoV-2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show-cased at the 15th Post-American Society of Hematology (ASH) and the 25th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9th-10th December 2020 and 7th-10th October 2021, respectively. The inaugural Post-ASH MPN workshop was set out in 2006 by John Goldman (deceased) and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
491-504Subventions
Organisme : Cancer Research UK
ID : 30721
Pays : United Kingdom
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Druker B. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(3):4808-4817.
Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
Brkic S, Meyer SC. Challenges and perspective for therapeutic targeting of myeloproliferative neoplasms. HemaSphere. 2021;5(1):e516.
Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation in JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391-2405.
Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667-679.
Mughal TI, Radich JP, Deininger MW, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016;101:541-558.
Mughal TI, Pemmaraju N, Radich JP, et al. Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. 2019;37:240-252.
Williams N, Lee J, Moore L, et al. Driver mutation acquistion in utero and childhood followed by lifelong clonal evolution underlies myeloproliferative neoplasms. Blood. 2020;136(Suppl 2).
Strickland M, Quek L, Psaila B. The immune landscape in BCR-ABL negative myeloproliferative neopalsms: inflammation, infections and opportunitires for immunotherapy. Br J Haematol. 2021;196:1149-1158. https://doi.org/10.1111/bjh.17850
Verstovsek S, Mesa R, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolotinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10:156. https://doi.org/10.1186/s13045-017-0527-7
Talpaz M, Kiladjian JJ. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated muyelofibrosis. Leukemia. 2021;35:1-17.
Verstovsek S, Egyed M, Lech-Maranda E, et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibition treated intermediate/high-risk myelofibrosis patients. Blood. 2020;136(Suppl 1):51-52.
Mughal TI, Pemmaraju N, Psaila B, et al. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. 2021;38:652-662.
Mascarenhas J, Gerds A, Kiladjian JJ, et al. PACIFICA: a randomized, controlled, phadse 3 study of pacritinib vs physician’s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia. Clin Lymph Myel Leuk. 2021;21(1):S352-S353.
Kamaz B, Mullaly A. COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia. 2021;35:279-281.
Krishnan A, Pagane M, Roshal M, et al. Evaluation of tagraxofusp (SL-401) alone and in combination with ruxolitinib for the treatment of myeloproliferative neoplasms. Blood. 2019;134(134):199-210.
Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380:1628-1637.
Pemmaraju N, Gupta V, Ali H, et al. MPN-377: updated results from a phase 1/2 clinical trial of tagraxofusp, a CD123-targeted therapy, in patients with poor-risk myelofibrosis. Lymphoma Myeloma Leuk. 2020;20(Suppl 1):S338-S339.
Holmstrom MO, Hasselbalch Riley C, Skov IM, Hasselbalch HC, Andersen MH, Andersen MH. Spontaneous T-cell responses against the immune checkpoint programmed-death-ligand (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. Oncoimmunology. 2018;7:e1433521.
Abou Dalle I, Kantarjian H, Daver N, et al. Phase II study of single agent nivolumab in patients with myelofibrosis. Ann Hematol. 2021;100:2957-2960.
Handlos Grauslund J, Holmstom MO, Jorgensen SG, et al. Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic myeloproliferative neoplasms. Front Oncol. 2021;11:637420.
Boasman K, Simmonds MJ, Rinaldi CR. Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome: potential new therapeutic targets. Blood. 2019;134(Suppl 1):5031.
Venugopal S, Mascarenhas J. Novel therapies in myeloproliferative neoplasms. J Hematol Oncol. 2020;13:162.
Mascarenhas J, Gerds A, Verstovsek S. Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia. 2021;35:3361-3363. https://doi.org/10.1038/s41375-021-01405-z
Zavidij O, Keller P, Cui L, et al. MPN-343: the BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutational status in myelofibrosis patiets in the phase 2 MANIFEST trial. Clin Lymph Myeloma. 2021;Suppl:S363-S364.
Pemmaraju N, Garcia JS, Potluri J, et al. The addition of navitoclax to ruxolitinib demonstrates efficacy within different high-risk populations in patients with relapsed/refractory myelofibrosis. Blood. 2020;136:39-40.
Yacoub A, Wang E, Rampal R, et al. Addition of parsaclisib (INCB050465), a PI3K delta inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with myelofibrosis. Br J Jaematol. 2021;193:9.
Kuykendall AT, Sun L, Mascrenhas J, et al. Favorable survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Ann Hematol. 2021. published online October 08, 2021. https://doi.org/10.1007/ss00277-021-04683-w
Atallah E, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and from whom? Haematologica. 2020;105(12):2738-2745.
Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia: 5-year update of the ENESTfreedom Trial. Leukemia. 2021;35(5):1344-1355.
Shah NP, Garcia-Gutierrez V, Jimenez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650-659.
Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: ther dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333-2340.
Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly disgnoaed chronic myeloid leukemia in chronic phase:ENESTnd 10-year analysis. Leukemia. 2021;35(2):440-453.
Hughes T, Mauro M, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315-2326.
Rea D, Maurp M, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in XML after 2 or more potent TKIs. Blood. 2021;138(21):2031-2041.
Reynaud D, Pietras E, Barry-Holson K, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011;20(5):661-673.
Welner RS, Amabile G, Bararia D, et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell. 2015;27(5):671-681.
Krause DS, Fulzele K, Catic A, et al. Differential regulation of myeloid leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell. 2015;27(5):671-681.
Burchert A, Sauselle S, Eigendorfl E, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015;29(6):1331-1335.
Rein LA, Rizzieri DA. A phase I trial incorporating natural killer (K-NK003) cells for patients with CML and MRD after TKI therapy. Blood. 2020;136(Suppl 1):5.
Carter BZ, Mak PY, Mu H, et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016;8(355):355ra117.
Herrmann O, Kuepper MK, Butow M, et al. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia. BMC Cancer. 2019;19(1):658.
Kuepper MK, Butow M, Herrmann O, et al. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia. 2019;33(8):1964-1977.
Parting O, Langer S, Kuepper MK, et al. Therapeutic inhibition of Fc-gamma-RIIb signaling targets leukemic stem cells in chronic myeloid leukemia. Leukemia. 2020;34(10):2635-2647.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeoid neoplasms and acute myeloid leukemia. Blood. 2016;127:2391-2405.
Mughal TI, Psaila B, DeAngelo D, Saglio G, VanEtten RA, Radich JP. Interrogating the molecular genetics of chronic myeloid malignancies for personalized management in 2021. Haematologica. 2021;106(7):1787-1793.
Royston D, Mead A, Psaila B. Application of single-cell approaches to study MPN biology. Hem Onc Clin. 2021;35(2):279-293.
Radakovich N, Nagy M, Nazha A. Machine learning in haematological malignancies. Lancet Haematol 2020;7(7):e541-e550.
Matek C, Kreppe S, Munzenmayer C, Haferlach T, Marr C. Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image database. Blood. 2021;138(20):1917-1927.
Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-339.
Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416-1430.
Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549-1556.
DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791-803.
Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52(11):1219-1226.
Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552-555.
Consortium ITP-CAoWG. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82-93.
Coombs CC, Gillis NK, Tan X, et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin cancer Res. 2018;24(23):5918-5924.
Jasek M, Gondek LP, Bejanyan N, et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia. 2010;24(1):216-219.
Marcellino BK, Farnoud N, Cassinat B, et al. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood advances. 2020;4(22):5735-5744.
Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023-2036.
Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 2018;9(5):439.
Cluzeau T, Sebert M, Rahme R, et al. Eprenetapopt plus azacitidine in tp53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des myelodysplasies (GFM). J Clin Oncol;2021:JCO2002342.
Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021:JCO2002341.
Swoboda DM, Sallman DA. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies. Best Pract Res Clin Haematol. 2020;33(4):101221.
Chao MP, Takimoto CH, Feng DD, et al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Frontiers in oncology. 2019;9:1380.
Sallman DA, McLemore AF, Aldrich AL, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136(24):2812-2823.
Miller PG, Gibson CJ, Mehta A, et al. Fitness landscape of clonal hematopoiesis under selective pressure of immune checkpoint blockade. JCO Precis Oncol. 2020;4.
Debureaux PE, Cassinat B, Soret-Dulphy J, et al. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Adv. 2020;4(15):3708-3715.
Tefferi A, Nicolosi M, Mudireddy M, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348-355.
Jutzi JS, Bogeska R, Nikoloski G, et al. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med. 2013;210(5):1003-1019.
Pahl HL. Sentinel mutations: the roses in the vineyard. Blood;138(21):2019-2020.
Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291-302.
Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
How J, Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers. 2020;12(7):1954.
Kucine N, Bergmann S, Krichevsky S, et al. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr Blood Cancer. 2021;68(3):e28888.
Valent P, Akin C, Hartmann K, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res 2017;77(6):1261-1270.
Shomali W, Gotlib JS. The new tool KIT in advanced systemic mastocytosis. Hematology (ASH Educ Program). 2018;1:127-136.
Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017;9(414). https://doi.org/10.1126/scitranslmed.aao1690
Sperr WR, Kundi M, Alvarez-Twose I, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol 2019;6(12):e638-e649.
Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635-641.
Pardanani A, Tefferi A. A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haem. 2010;84:371-378.
Gotlib J, Pardanani A, Akin C, et al. International working group-myeloproliferative neoplasms research and treatment (IWG-MRT) & European competence network on mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013;121(13):2393-2401.
Shomali W, Gotlib JS. Response criteria in advanced suystemic mastocytosis: evolution in the era of KIT inhibitors. Int J Meol Sci. 2021;22:2983.
Jawhar M, Schwaab J, Alvarez-Twose I, et al. MARS: mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37(31):2846-2856.
Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530-2541.
Gotlib J, Radia DH, George TI, et al. Avapritinib induces responses in patients with advanced systemic mastocytosis (advSM), regardless of prior midostaurin therapy [abstract]. Hemasphere. 2020;4:EP1079.
Bose P, Verstovsek S. Avapritinib for systemic mastocytosis. Expet Rev Hematol. 2021;14(8):687-696.
Gotlib JS, Radia DH, George TI, et al. Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving avapritinib in the phase I EXPLORER study [abstract]. Blood. 2020;136:37-38.
Valent P, Bauer K, Sadovnik I, et al. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in AML: perspectives and open issues. Stem Cells Transl Med. 2020;9(11):1331-1343.
Rathert P, Roth M, Neumann T, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525:543-547.
Van Gils N, Denkers F, Smit L. Escape from treatment; the different faces of leukemic stem cells and therapy resistance in AML. Front Oncol. 2021;11. https://doi.org/10.3389/fonc.2021.659253
Guo L, Zeng H, Guzman AG, et al. A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. Nat Comm. 2020;11:740.
Bauer K, Berghoff AS, Preusser M, et al. Degradation of BRD4- a promising treatment approach not only for hematologic but also solid cancer. Am J Cancer Res. 2021;11(2):530-545.
Tettamani S, Pievani A, Bioni A, Dotti G, Serafini M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia. 36; 2021:13-22. https://doi.org/10.1038/s41375-021-01350-x
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137-2145.
Konopleva M. Mechansims for resistance in AML insights into molecular pathways mediating resistance to venetoclax. Best Pract Res Clin Hematol. 2021;34(1):101251.
DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791-803.
Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 2016.
Kuusanmaki H, Leppa AM, Polonen P, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2019.
Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov 2020;10:536-551.
Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018.
Jones CL, Stevens BM, D'Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724-740.
Stevens BM, Jones CL, Pollyea DA, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1:1176-1187.
Lee JS, Roberts A, Juarez D, et al. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018;10(445). https://doi.org/10.1126/scitranslmed.aaq1240
Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355-365.
Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018;132:67-77.
Bolton-Gillespie E, Schemionek M, Klein HU, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013;121:4175-4183.
Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 2012;119:4253-4263.
Nieborowska-Skorska M, Maifrede S, Dasgupta Y, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017;130:2848-2859.
Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47:497-510.
Karanam K, Kafri R, Loewer A, Lahav G. Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. Mol Cell. 2012;47:320-329.
Feng Z, Scott SP, Bussen W, et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci U S A. 2011;108:686-691.
Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015;66:455-470.
Kontandreopoulou CN, Diamantopoulous PT, Tibalexi D, Giannakopoulou N, Viniou NA. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 2021;5:4794-4805. https://doi.org/10.1182/bloodadvances.2021004638
Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 2013;122:1293-1304.
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017;127:2392-2406.
Maifrede S, Martinez E, Nieborowska-Skorska M, et al. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Adv. 2017;1:14671472.
Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, et al. Simultaneous targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells. Cell Rep 2018;23:3127-3136.
Maifrede S, Nieborowska-Skorska M, Golovine K, et al. TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors. Cancer Res. 2021;81(19):5089-5101.
Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12:68-78.
Le BV, Podszywalow-Bartnicka P, Maifrede S, et al. TGFβR-SMAD3 signaling induces resistance to PARP inhibitors in the bone marrow microenvironment. Cell Rep 2020;33:108221.
Barbui T, Masciulli A, Marfisi MR, et al. White blood count and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560-561.
Ang SO, Chen H, Hirota K, et al. Congenital chuvash polycythemia: altered oxygen homeostasis due to homozygosity for a hypomorphic VHL allele. Nat Genet. 2002;32(4):614-621.
Reeves BN, Kim SJ, Song J, et al. Tissue factor activity is increased in neutrophils from JAK2 V617F-mutated essential thrombocythemia and polycythemia vera patients. Am J Hematol. 2021;97. Epub ahead of print. PMID: 34748652. https://doi.org/10.1002/ajh.26402
Yoon D, Kim H, Jang M, et al. Characterization of tissue-specific HIF-1 and HIF-2 regulatory elements of erythropoetin gene. Blood. 2008;112(11):4763.
Prchal J, Gordeuk VR. HIF-2 inhibitor, erythrocytosis, and pulmonary hypertension. Blood. 2021;137(18):2424-2425.
Song J, Sergueeva A, Maisnikova G, et al. Phlebotomy-induced iron deficiency increases the expression of prothrombotic genes. Blood. ;136(Suppl 1):11-12.
Gangaraju R, Song J, Kim SJ, et al. Thrombotic, inflammation, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020;4(6):1115-1130.